Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cellsYulong Gao, Mark J. Smyth, Nicola Waddell et al.|Nature Immunology|2017Cited by 639
PI3K-AKT-mTOR inhibition in cancer immunotherapy, reduxJake S. O’Donnell, Mario Mandalà, Daniela Massi et al.|Seminars in Cancer Biology|2017Cited by 366
Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor ImmunityXian-Yang Li, Mark J. Smyth, Achim K. Moesta et al.|Cancer Discovery|2019Cited by 269
The role of NK cells and CD39 in the immunological control of tumor metastasesHaiyan Zhang, Mark J. Smyth, Dipti Vijayan et al.|OncoImmunology|2019Cited by 87
Control of Metastases via Myeloid CD39 and NK Cell Effector FunctionJuming Yan, Mark J. Smyth, Xian-Yang Li et al.|Cancer Immunology Research|2020Cited by 81